

## Community treatment of high risk patients

Community treatments for Covid-19 positive patients who fall into the highest risk categories (see below) are available.

Treatment with an oral antiviral called Paxlovid® will be considered first-line.

If treatment with paxlovid is not suitable due to contraindications / interactions then alternatively an IV infusion of a neutralising monoclonal antibody (nMAB) called Sotrovimab will be offered.

### Eligibility Criteria

Patients must meet all of the eligibility criteria and none of the exclusion criteria:

- COVID-19 infection is confirmed by a PCR or LFT test within the last 5-7 days

**AND**

- [Symptomatic with COVID-19](#), with symptom onset in the last 5-7 days and showing no signs of clinical recovery

**AND**

- A member of a 'highest' risk group (see [here](#) for definitions)

### Exclusion criteria

Patients are not eligible for treatment in the community if they meet any of the following:

- Require hospitalisation for COVID-19
- New supplemental oxygen requirement specifically for the management of COVID-19 symptoms.

Note for patients who are not a member of a 'highest' risk group but who are over 50 years of age, or who are aged over 18 and have a health condition that increases their risk (priority groups 1-9), antiviral treatments will only be available through a UK trial (PANORAMIC) in which eligible patients will be randomised to receive an antiviral or standard care. Patients who may be suitable for this trial should be signposted to [www.panoramictrial.org](http://www.panoramictrial.org) or phone 0808 1560017

### Referral and treatment

Eligible patients can either self-refer or be referred in by a Health care professional via the links below. The local team will then contact the patient to assess eligibility and to arrange treatment when indicated

Patients who fall into the highest risk category can collect free LFT tests from selected local community pharmacies - see here for further information [Get tested for coronavirus \(COVID-19\) | GOV.WALES](#)

### **How to Refer**

- A self-referral form (for patients to complete) can be found on this webpage: [COVID-19 treatments | GOV.WALES](#)
- A referral form for health care professionals to complete on behalf of the patient can be found [here](#)

Alternatively, eligible patients may also be advised to contact 111 (NHS 111 Wales) for assessment and referral to the local service.

Please note Paxlovid is not available within the normal medication supply chain and so will not be accessible via FP10 from community pharmacies.

### **Patient information**

Patients can be directed to this website for further information: <https://www.wmic.wales.nhs.uk/navs-cymru/>

### **Resources for the antiviral teams**

Paxlovid has a number of significant drug-drug interactions and so concurrent medications must be carefully checked for all patients using the [Liverpool COVID-19 Interactions \(covid19-druginteractions.org\) checker](https://www.liverpool.ac.uk/covid19-druginteractions.org/).

A Paxlovid decision aid is also available for advice on dosing in renal / hepatic impairment, patients on chemotherapy and for advice on managing some of the more common drug-drug interactions: [Paxlovid decision aid](#)

The SPC is available here: [Paxlovid 150 mg/100 mg film-coated tablets - Patient Information Leaflet \(PIL\) - \(emc\) \(medicines.org.uk\)](#)

Additional interaction information may also be available via UpToDate.

Last reviewed: Feb 2024

---